接受派姆单抗治疗的晚期尿路上皮癌患者中 C 反应蛋白flare 反应的影响。
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
机构信息
Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
出版信息
In Vivo. 2021 Nov-Dec;35(6):3563-3568. doi: 10.21873/invivo.12659.
Abstract
BACKGROUND/AIM: To clarify the clinical significance of the temporary elevated C-reactive protein (CRP) levels followed by a decrease below baseline (CRP flare response) after administration of pembrolizumab to patients with advanced urothelial carcinoma (UC).
PATIENTS AND METHODS
We retrospectively reviewed 31 patients with advanced UC who received pembrolizumab. Patients were categorized into 3 groups (flare-responder, responder, non-responder) according to early CRP kinetics. Intergroup tumor response and survivals were compared.
RESULTS
Objective response rates of flare-responder, responder, and non-responder groups were 75%, 80%, and 26%, respectively. Median overall survival was not reached in flare-responder and responder groups, and was 10.2 months in the non-responder group (p=0.03). Furthermore, the flare-responder group did not reach median progression-free survival, and for the responder and non-responder groups it was 15.2 and 2.8 months, respectively (p=0.03).
CONCLUSION
CRP flare response might be a promising biomarker in patients with advanced UC who received pembrolizumab.
摘要
背景/目的：阐明在晚期尿路上皮癌（UC）患者中接受派姆单抗治疗后 C 反应蛋白（CRP）水平暂时升高后下降至基线以下（CRP 爆发反应）的临床意义。
患者和方法
我们回顾性分析了 31 例接受派姆单抗治疗的晚期 UC 患者。根据早期 CRP 动力学，患者分为 3 组（爆发反应组、反应组、无反应组）。比较组间肿瘤反应和生存情况。
结果
爆发反应组、反应组和无反应组的客观缓解率分别为 75%、80%和 26%。爆发反应组和反应组的中位总生存期未达到，无反应组为 10.2 个月（p=0.03）。此外，爆发反应组无进展生存期未达到，反应组和无反应组分别为 15.2 个月和 2.8 个月（p=0.03）。
结论
在接受派姆单抗治疗的晚期 UC 患者中，CRP 爆发反应可能是一种有前途的生物标志物。
相似文献
1
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.接受派姆单抗治疗的晚期尿路上皮癌患者中 C 反应蛋白flare 反应的影响。
In Vivo. 2021 Nov-Dec;35(6):3563-3568. doi: 10.21873/invivo.12659.
2
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.早期 C 反应蛋白动力学可预测帕博利珠单抗治疗晚期尿路上皮癌患者的生存情况。
Cancer Immunol Immunother. 2021 Mar;70(3):657-665. doi: 10.1007/s00262-020-02709-2. Epub 2020 Sep 2.
3
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.C反应蛋白升高预测转移性尿路上皮癌对抗PD-(L)1免疫检查点阻断的反应。
Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30.
4
Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.C-反应蛋白flare 反应对接受纳武利尤单抗治疗的转移性肾细胞癌患者肿瘤学结局的影响。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001564.
5
Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.化疗后对含铂化疗方案治疗失败的晚期尿路上皮癌混合应答帕博利珠单抗的临床疗效。
In Vivo. 2021 Sep-Oct;35(5):2869-2874. doi: 10.21873/invivo.12575.
6
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.比较转移性尿路上皮癌患者接受avelumab 或 pembrolizumab 治疗后恩福妥单抗的疗效：来自日本多机构研究的真实世界数据。
J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2.
7
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.帕博利珠单抗二线治疗瑞典局部晚期或转移性尿路上皮癌的成本效果分析。
Eur Urol Oncol. 2020 Oct;3(5):663-670. doi: 10.1016/j.euo.2018.09.012. Epub 2018 Nov 22.
8
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.C 反应蛋白升高可预测非小细胞肺癌对检查点抑制剂治疗的反应。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004024.
9
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.质子泵抑制剂的使用对帕博利珠单抗治疗晚期尿路上皮癌疗效的影响。
Anticancer Res. 2022 Mar;42(3):1629-1634. doi: 10.21873/anticanres.15638.
10
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.帕博利珠单抗对比化疗治疗日本患者复发性、晚期尿路上皮癌：III 期 KEYNOTE-045 试验的亚组分析。
Int J Clin Oncol. 2020 Jan;25(1):165-174. doi: 10.1007/s10147-019-01545-4. Epub 2019 Nov 15.
引用本文的文献
1
Integrated Early CRP Kinetics and Plasma EBV DNA Clearance as Prognostic Biomarkers in De Novo Metastatic Nasopharyngeal Carcinoma Treated with First-Line Chemoimmunotherapy.综合早期C反应蛋白动力学和血浆EB病毒DNA清除率作为一线化疗免疫治疗的初治转移性鼻咽癌预后生物标志物
J Inflamm Res. 2025 May 26;18:6783-6794. doi: 10.2147/JIR.S512808. eCollection 2025.
2
Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.免疫检查点抑制剂治疗的尿路上皮癌患者治疗前血液炎症生物标志物的预后和预测价值：一项系统评价和荟萃分析
Front Immunol. 2025 Mar 17;16:1554048. doi: 10.3389/fimmu.2025.1554048. eCollection 2025.
3
Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes.帕博利珠单抗治疗晚期尿路上皮癌患者时C反应蛋白早期动力学的临床意义：炎症反应和基线水平可预测肿瘤学结局。
Oncol Lett. 2024 Oct 11;28(6):603. doi: 10.3892/ol.2024.14736. eCollection 2024 Dec.
4
C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer.C反应蛋白动力学作为食管胃癌免疫检查点抑制剂长期疗效的预测标志物
BJC Rep. 2023 Aug 2;1(1):7. doi: 10.1038/s44276-023-00005-x.
5
C-Reactive Protein Kinetic as a Potential Predictive and Prognostic Factor during Treatment with Checkpoint Inhibitors in R/M-HNSCC.C反应蛋白动力学作为复发/转移头颈部鳞状细胞癌接受检查点抑制剂治疗期间潜在的预测和预后因素
Cancers (Basel). 2024 Jun 30;16(13):2424. doi: 10.3390/cancers16132424.
6
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours.整体肿瘤医学方法支持免疫检查点抑制剂治疗实体瘤。
Curr Oncol Rep. 2024 Feb;26(2):164-174. doi: 10.1007/s11912-023-01492-4. Epub 2024 Jan 9.
7
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.免疫检查点抑制剂治疗患者的无癌预测治疗反应和死亡率的 C 反应蛋白早期动力学：一项多中心队列研究。
J Immunother Cancer. 2023 Dec 14;11(12):e007765. doi: 10.1136/jitc-2023-007765.
8
Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors.一线免疫检查点抑制剂治疗转移性肾细胞癌患者的真实世界队列中，C 反应蛋白早期动力学作为生存预后标志物。
Clin Transl Oncol. 2024 May;26(5):1117-1128. doi: 10.1007/s12094-023-03317-z. Epub 2023 Sep 11.
9
The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma.帕博利珠单抗两疗程治疗后中性粒细胞与淋巴细胞比值对转移性尿路上皮癌患者肿瘤学结局的影响
Biomedicines. 2022 Jul 6;10(7):1609. doi: 10.3390/biomedicines10071609.
本文引用的文献
1
Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.帕博利珠单抗治疗转移性尿路上皮癌的疗效和安全性：日本单中心回顾性分析。
Cancer Rep (Hoboken). 2021 Dec;4(6):e1398. doi: 10.1002/cnr2.1398. Epub 2021 May 2.
2
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.IL-6 信号在巨噬细胞中对于免疫治疗驱动的肿瘤消退是必需的。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2021-002460.
3
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.预后营养指数对铂类化疗耐药的转移性尿路上皮癌患者接受派姆单抗治疗的预测影响。
Anticancer Res. 2021 Mar;41(3):1607-1614. doi: 10.21873/anticanres.14922.
4
Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.血细胞计数生物标志物可预测派姆单抗作为二线治疗晚期尿路上皮癌的疗效。
Anticancer Res. 2021 Mar;41(3):1599-1606. doi: 10.21873/anticanres.14921.
5
Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.C-反应蛋白flare 反应对接受纳武利尤单抗治疗的转移性肾细胞癌患者肿瘤学结局的影响。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001564.
6
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.帕博利珠单抗治疗化疗耐药性尿路上皮癌患者预后的风险分层
Cancer Sci. 2021 Feb;112(2):760-773. doi: 10.1111/cas.14762. Epub 2020 Dec 21.
7
Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.帕博利珠单抗治疗晚期尿路上皮癌患者的预处理风险分层和治疗后中性粒细胞/淋巴细胞比值变化的预后价值。
Int J Clin Oncol. 2021 Jan;26(1):169-177. doi: 10.1007/s10147-020-01784-w. Epub 2020 Sep 18.
8
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.早期 C 反应蛋白动力学可预测帕博利珠单抗治疗晚期尿路上皮癌患者的生存情况。
Cancer Immunol Immunother. 2021 Mar;70(3):657-665. doi: 10.1007/s00262-020-02709-2. Epub 2020 Sep 2.
9
Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.帕博利珠单抗治疗晚期尿路上皮癌患者的预后结局和安全性：真实世界临床实践经验。
Int J Clin Oncol. 2020 May;25(5):899-905. doi: 10.1007/s10147-019-01613-9. Epub 2020 Jan 7.
10
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.帕博利珠单抗对比化疗治疗日本患者复发性、晚期尿路上皮癌：III 期 KEYNOTE-045 试验的亚组分析。
Int J Clin Oncol. 2020 Jan;25(1):165-174. doi: 10.1007/s10147-019-01545-4. Epub 2019 Nov 15.
Zotero 插件